Clinical Trial for those with HVC, cirrhosis, HCC awaiting tranplant

[HectorSF]

There will only be 40 people world-wide (US, Europe and New Zealand) in this study you you have  HVC, cirrhosis, HCC and awaiting transplant within the next 6 months this may be the best way to cure yourself of hepatitis C for good. Two oral drugs NO interferon. GS-7977 + Ribavirin. Currently recruiting.

"An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant"
This study is currently recruiting participants.
Verified April 2012 by Gilead Sciences
Study NCT01559844   Information provided by Gilead Sciences

http://clinicaltrials.gov/ct2/show/NCT01559844?term=gilead+gs-7977&rank=4

Current Primary Outcome Measures - To determine if the administration of a combination of GS 7977 and ribavirin to HCV-infected subjects with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior to undergoing liver transplantation for up to 24 weeks can prevent post-transplant re-infection as determined by a sustained post-transplant virological response (HCV RNA  10e4 IU/mL at Screening
Patients meeting the MILAN criteria undergoing liver transplant for HCC secondary to HCV with a MELD of  10 mg/day) in the Pre-transplant treatment period.
History of previous solid organ transplantation
Evidence of renal impairment (CrCl < 60 mL/min) calculated by the Cockroft-Gault equation.
History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, porphyria, or poorly controlled diabetes, cancer other than HCC, or a history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study. Patients with clinical signs or symptoms of acute pancreatitis with elevated lipase (at Screening or during the Screening period)
Known hypersensitivity to RBV, the study investigational medicinal product, the metabolites, or formulation excipients.
History of having received any systemic antineoplastic (including sorafenib) or immunomodulatory treatment (including radiation) within 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study (excluding a local regional therapy such as TACE).
Treatment with Transcatheter arterial chemoembolization (TACE) or radio frequency ablation (RFA) within 30 days prior to the first dose.
Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to first dose administration at the Baseline/Day 1 Visit.

Cheers!
Hector

[ceanothus]

So far, so good, and I hope it all continues going your way. The study sounds like an extremely good idea – almost a no-brainer!. I hope the results live up to the hopes and expectations, and I especially hope that you DO end up included. Good luck!
-Saelon

[Dee1956]

I am praying for you.  You deserve the biggest break of everyone here
It will happen
Dee

[yodennis]

Man my fingers are crossed for you (I know that you know that I know that such metaphors have about as much to do with you getting into the study as the weather but I'll still keep them crossed). d

[jsf52]

You are in my prayers.  You deserve this chance more than anyone else.  Good luck.  

[viaduk]

It is fate/karma/etc. that you will be enrolled into this trial and get the golden HCV.    You deserve a big break, and I hope that this one does it for you. I'm glad that you followed up on this study,  Sounds perfect for you!

Be well!

[nan535]

Just saw this thread.  I wish you the best because you deserve it.
I know how exhausting this all is and yet you find the time to GIVE to others.
I understand you...all will go well.

Nan